EQS-News: Formycon included in TecDAX Index of Deutsche Börse
Formycon AG is headquartered in Munich and is listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and has been part of the selection index SDAX since ...
PharmiWeb15h
Formycon included in TecDAX Index of Deutsche Börse
MiscellaneousFormycon included in TecDAX Index of Deutsche Börse 09.01.2025 / 15:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release // January 9, ...
Formycon and Fresenius Kabi Canada Receive Health Canada s Approval for FYB202/Otulfi (ustekinumab), a Biosimilar to Stelara
Approved by Health Canada for Both Subcutaneous and Intravenous Formulations to Treat Serious Inflammatory Diseases Health Canada Joins the FDA and the European Commission in Granting Regulatory ...
EQS-News: Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...
Le Lézard1d
Fresenius Kabi Canada has received a Health Canada Notice of Compliance (NOC) for Otulfitm* an Ustekinumab Biosimilar
OtulfiTM received a Health Canada Notice of Compliance (NOC) approval on December 30th for both subcutaneous and intravenous formulationsWith this approval, Fresenius Kabi Canada's immunology ...
PharmiWeb1d
Formycon and Fresenius Kabi Canada receive Health…
Regulatory ApprovalFormycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 08.01.2025 / 14:30 CET/CESTThe issuer is solely ...
Pharmaceutical Technology4d
Pembrolizumab biosimilar by Formycon for Non-Small Cell Lung Cancer: Likelihood of Approval
Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer.
Pharmaceutical Technology4d
Pembrolizumab biosimilar by Formycon for Melanoma: Likelihood of Approval
FYB-206 is under development for the treatment of malignant melanoma (black skin cancer) and non-small cell lung cancer. The drug candidate is a pembrolizumab biosimilar. It acts by targeting ...
Drug Store News10d
FDA approves Celltrion's Stelara biosimilar
Steqeyma is approved for adult and pediatric patients with plaque psoriasis and active psoriatic arthritis as well as adults ...
BBC16d
Vladimir Putin
Watch BBC's Steve Rosenberg challenge Putin on his 25 years in power in Russia. Video, 00:03:33Watch BBC's Steve Rosenberg challenge Putin on his 25 years in power in Russia ...
Press Gazette22d
Top 50 news websites in the world: AP and NBC see more than 50% monthly surge
President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...
ophthalmologytimes25d
EMA CHMP issues positive opinion for aflibercept biosimilar from Celltrion
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) announced opinions for three biosimilar candidates from Celltrion, including a biosimilar for reference ...